<a href="https://www.fiercebiotech.com/biotech/ucb-inks-2b-candid-buyout-join-gilead-autoimmune-field" hreflang="en">UCB inks $2B Candid buyout to join Gilead in autoimmune field</a>
UCB has acquired Candid Therapeutics for $2 billion to enhance its pipeline of T-cell engagers targeting autoimmune diseases, positioning itself to compete with Gilead in this emerging market. The acquisition includes Candid's lead candidate, cizutamig, which is nearing phase 2 trials and shows promise in achieving long-term remission for autoimmune conditions.
UCB's $2 billion acquisition of Candid Therapeutics represents a strategic move to expand its T-cell engager (TCE) pipeline, capitalizing on the potential of TCEs to offer outpatient dosing and long-term remission in autoimmune diseases. This acquisition signals a growing interest and investment opportunity in TCEs as a promising alternative to CAR-T therapies in the autoimmune space, highlighting the importance of monitoring advancements in bispecific antibody and TCE technologies for stakeholders in healthtech and biotech.